InnoCare Doses First Patient in Phase III Trial of ICP-488 for Psoriasis in China InnoCare Pharma, a leading biopharmaceutical company dedicated to developing innovative treatments for cancer and autoimmune diseases, has announced a significant milestone in its clinical development efforts.…
BPGbio to Present Novel E2-Based TPD Program at 5th Annual Summit BPGbio, Inc., a leading biology-first, AI-powered, clinical-stage biopharmaceutical company focused on mitochondrial biology and protein homeostasis, has announced its participation in the 5th Annual Targeted Protein Degradation (TPD) and…
MiNA Therapeutics Adds Norbert Bischofberger to Board, Bríd Ryan as CSO MiNA Therapeutics Limited, a leader in the development of small activating RNA (RNAa) therapeutics, has announced key leadership changes to strengthen its scientific and strategic capabilities. The company has…
Triastek announced that on February 27, 2025, its proprietary 3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) product, T20G, received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This milestone follows the product’s prior IND clearance…
Scholar Rock Presents Comprehensive Phase 3 SAPPHIRE Trial Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference Scholar Rock, a late-stage biopharmaceutical company committed to advancing groundbreaking treatments for neuromuscular diseases, cardiometabolic disorders, and other serious conditions influenced…
Biote Announces Fourth Quarter and Full-Year 2024 Financial Results Biote, a leading provider of personalized hormone optimization and therapeutic wellness solutions, has released its financial results for the fourth quarter and full year ended December 31, 2024. The company reported…
Merck’s Phase 3 Trials Show DOR/ISL Maintains HIV-1 Suppression at 48 Weeks Merck, known as MSD outside of the United States and Canada, has announced promising results from two pivotal Phase 3 clinical trials evaluating its investigational, once-daily, oral, two-drug…
Gilead Unveils New HIV Treatment Data at CROI 2025 Gilead Sciences, Inc. has unveiled a significant array of late-breaking data and multiple oral presentations from its groundbreaking HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections…
PharmaCord & Mercalis Merge to Advance Biopharma Solutions PharmaCord LLC (“PharmaCord”), a leading provider of patient services for the biopharmaceutical industry, and Mercalis, an integrated life sciences commercialization partner, have announced a merger to create one of the largest independent…
InTandem Capital Invests in Clinilabs InTandem Capital Partners (“InTandem Capital” or the “Firm”), a private equity firm specializing in healthcare services, has officially announced its strategic partnership with Clinilabs (the “Company”). Clinilabs is a global, full-service contract research organization (CRO)…
Generative AI Revolutionizes Health Technology Assessment Landscape: Trinity Life Sciences Enhances HTA Vision Trinity Life Sciences, a leading provider of strategy, insights, and analytics for the life sciences industry, has announced a groundbreaking enhancement to its HTA Vision platform. The…
Cellino and Matricelf Partner to Scale Personalized Spinal Cord Injury Treatments Cellino and Matricelf (TASE: MTLF) announced today a groundbreaking global collaboration aimed at accelerating the biomanufacturing of personalized spinal cord injury treatments. This partnership integrates Cellino’s cutting-edge Nebula™ technology…